Interleukin-1β induces blood-brain barrier disruption by downregulating sonic hedgehog in astrocytes

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Wang, Yue ^a   Jin, Shijie ^a   Sonobe, Yoshifumi ^a   Cheng, Yi ^a   Horiuchi, Hiroshi ^a   Parajuli, Bijay ^a   Kawanokuchi, Jun ^a   Mizuno, Tetsuya ^a   Takeuchi, Hideyuki ^a   Suzumura, Akio ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL2 CHEMOKINE; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SONIC HEDGEHOG PROTEIN; TIGHT JUNCTION PROTEIN; CHEMOKINE; IL1B PROTEIN, MOUSE; SHH PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER DISRUPTION; CELL FUNCTION; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOCOMPETENT CELL; MEMBRANE DAMAGE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEWBORN; NONHUMAN; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CELL LINE; GENE EXPRESSION; GENETICS; METABOLISM; PARACRINE SIGNALING; PHYSIOLOGY; TIGHT JUNCTION;

ERINACEIDAE;

ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; CELL LINE; CHEMOKINES; DOWN-REGULATION; GENE EXPRESSION; HEDGEHOG PROTEINS; INTERLEUKIN-1BETA; MICE; PARACRINE COMMUNICATION; TIGHT JUNCTIONS;

EID: 84908013297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110024     Document Type: Article

References (47)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25.
2. Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO (2012) Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9: 23.
3. Hayashi Y, Nomura M, Yamagishi S, Harada S, Yamashita J, et al. (1997) Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 19: 13-26.
4. Janzer RC, Raff MC (1987) Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325: 253-257.
5. Alvarez JI, Katayama T, Prat A (2013) Glial influence on the blood brain barrier. Glia 61: 1939-1958.
6. Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, et al. (2011) The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 334: 1727-1731.
7. Osterlund T, Kogerman P (2006) Hedgehog signalling: how to get from Smo to Ci and Gli. Trends Cell Biol 16: 176-180.
8. Carvey PM, Hendey B, Monahan AJ (2009) The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem 111: 291-314.
9. Erickson MA, Banks WA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 33: 1500-1513.
10. Grammas P, Martinez J, Miller B (2011) Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev Mol Med 13: e19.
11. Minagar A, Alexander JS (2003) Blood-brain barrier disruption in multiple sclerosis. Mult Scler 9: 540-549.
12. Weiss N, Miller F, Cazaubon S, Couraud PO (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788: 842-857.
13. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.
14. Kempermann G, Neumann H (2003) Neuroscience. Microglia: the enemy within? Science 302: 1689-1690.
15. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
16. Argaw AT, Zhang Y, Snyder BJ, Zhao ML, Kopp N, et al. (2006) IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J Immunol 177: 5574-5584.
17. Blamire AM, Anthony DC, Rajagopalan B, Sibson NR, Perry VH, et al. (2000) Interleukin-1beta -induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study. J Neurosci 20: 8153-8159.
18. Laflamme N, Lacroix S, Rivest S (1999) An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 19: 10923-10930.
19. Liang J, Takeuchi H, Doi Y, Kawanokuchi J, Sonobe Y, et al. (2008) Excitatory amino acid transporter expression by astrocytes is neuroprotective against microglial excitotoxicity. Brain Res 1210: 11-19.
20. Suzumura A, Lavi E, Weiss SR, Silberberg DH (1986) Coronavirus infection induces H-2 antigen expression on oligodendrocytes and astrocytes. Science 232: 991-993.
21. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T (1992) Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267: 20383-20391.
22. Sonobe Y, Takeuchi H, Kataoka K, Li H, Jin S, et al. (2009) Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner. J Biol Chem 284: 31834-31842.
23. Cheng Y, Takeuchi H, Sonobe Y, Jin S, Wang Y, et al. (2014) Sirtuin 1 attenuates oxidative stress via upregulation of superoxide dismutase 2 and catalase in astrocytes. J Neuroimmunol 269: 38-43.
24. Wang J, Takeuchi H, Sonobe Y, Jin S, Mizuno T, et al. (2008) Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A 105: 3915-3920.
25. Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, et al. (2013) Fingolimod phosphate attenuates oligomeric amyloid beta-induced neurotoxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS One 8: e61988.
26. Herx LM, Yong VW (2001) Interleukin-1 beta is required for the early evolution of reactive astrogliosis following CNS lesion. J Neuropathol Exp Neurol 60: 961-971.
27. Chakraborty S, Kaushik DK, Gupta M, Basu A (2010) Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 88: 1615-1631.
28. Aronica E, Ravizza T, Zurolo E, Vezzani A (2012) Astrocyte immune responses in epilepsy. Glia 60: 1258-1268.
29. Martinon F, Tschopp J (2005) NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26: 447-454.
30. Friedman WJ, Thakur S, Seidman L, Rabson AB (1996) Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NFkappaB. J Biol Chem 271: 31115-31120.
31. Glazner GW, Camandola S, Mattson MP (2000) Nuclear factor-kappaB mediates the cell survival-promoting action of activity-dependent neurotrophic factor peptide-9. J Neurochem 75: 101-108.
32. Walsh JG, Muruve DA, Power C (2014) Inflammasomes in the CNS. Nat Rev Neurosci 15: 84-97.
33. Parajuli B, Sonobe Y, Horiuchi H, Takeuchi H, Mizuno T, et al. (2013) Oligomeric amyloid beta induces IL-1beta processing via production of ROS: implication in Alzheimer's disease. Cell Death Dis 4: e975.
34. Muldoon LL, Alvarez JI, Begley DJ, Boado RJ, Del Zoppo GJ, et al. (2013) Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab 33: 13-21.
35. Nachtergaele S, Mydock LK, Krishnan K, Rammohan J, Schlesinger PH, et al. (2012) Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol 8: 211-220.
36. Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 103: 21-80.
37. Rosenberg GA (2012) Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 32: 1139-1151.
38. Frequin ST, Barkhof F, Lamers KJ, Hommes OR (1992) The effects of highdose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis. J Neuroimmunol 40: 265-272.
39. Kraus J, Oschmann P (2006) The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 11: 755-762.
40. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23.
41. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933.
42. Martiney JA, Litwak M, Berman JW, Arezzo JC, Brosnan CF (1990) Pathophysiologic effect of interleukin-1b in the rabbit retina. Am J Pathol 137: 1411-1423.
43. Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, et al. (1996) Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383: 407-413.
44. Araujo GL, Araujo JA, Schroeder T, Tort AB, Costa MR (2014) Sonic hedgehog signaling regulates mode of cell division of early cerebral cortex progenitors and increases astrogliogenesis. Front Cell Neurosci 8: 77.
45. Traiffort E, Angot E, Ruat M (2010) Sonic Hedgehog signaling in the mammalian brain. J Neurochem 113: 576-590.
46. Mastronardi FG, daCruz LA, Wang H, Boggs J, Moscarello MA (2003) The amount of sonic hedgehog in multiple sclerosis white matter is decreased and cleavage to the signaling peptide is deficient. Mult Scler 9: 362-371.
47. Mastronardi FG, Min W, Wang H, Winer S, Dosch M, et al. (2004) Attenuation of experimental autoimmune encephalomyelitis and nonimmune demyelination by IFN-beta plus vitamin B12: treatment to modify notch-1/sonic hedgehog balance. J Immunol 172: 6418-6426.